# FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

> **NCT05395052** · PHASE1 · TERMINATED · sponsor: **Fate Therapeutics** · enrollment: 5 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Head and Neck Cancer
- GastroEsophageal Cancer

## Interventions

- **DRUG:** FT536
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** IL-2
- **COMBINATION_PRODUCT:** Avelumab
- **COMBINATION_PRODUCT:** Pembrolizumab
- **COMBINATION_PRODUCT:** Nivolumab
- **COMBINATION_PRODUCT:** Atezolizumab
- **COMBINATION_PRODUCT:** Trastuzumab
- **COMBINATION_PRODUCT:** Cetuximab
- **COMBINATION_PRODUCT:** Amivantamab
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT05395052
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-31
- **Primary completion:** 2023-08-11
- **Final completion:** 2023-08-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** This study was terminated by the Sponsor.
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05395052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05395052, "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05395052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*